DLBCL
Clinical trials for DLBCL explained in plain language.
Never miss a new study
Get alerted when new DLBCL trials appear
Sign up with your email to follow new studies for DLBCL, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Promising new pill combo aims to boost lymphoma cure rates
⭐️ CURE ⭐️ Recruiting nowThis study tests whether adding the drug acalabrutinib to standard chemotherapy can cure more people with untreated diffuse large B-cell lymphoma, an aggressive blood cancer. About 132 adults will take the pill twice daily for up to 14 days, then receive standard chemo and rituxi…
Matched conditions: DLBCL
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: ⭐️ CURE ⭐️
Last updated May 18, 2026 12:13 UTC
-
Engineered immune cells take on Hard-to-Treat lymphoma
Disease control Recruiting nowThis early-phase trial tests a personalized cell therapy for people with a specific type of lymphoma linked to the Epstein-Barr virus (EBV). The treatment uses the patient's own immune cells, modified to recognize and attack EBV-infected cancer cells. The main goals are to check …
Matched conditions: DLBCL
Phase: EARLY_PHASE1 • Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated May 26, 2026 08:19 UTC
-
New drug SGR-1505 enters early human testing for blood cancers
Disease control Recruiting nowThis early-phase study tests a new drug called SGR-1505 in about 98 adults with various B-cell blood cancers (like lymphoma and leukemia). The main goals are to check safety and find the best dose. Participants will receive the drug and be monitored for side effects and how the d…
Matched conditions: DLBCL
Phase: PHASE1 • Sponsor: Schrödinger, Inc. • Aim: Disease control
Last updated May 26, 2026 08:19 UTC
-
New CAR T-Cell therapy targets tough lymphoma cancers
Disease control Recruiting nowThis early-phase study tests a new treatment called SynKIR-310 for adults with B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior therapies. The treatment uses a patient's own immune cells, modified to recognize and attack cancer cells. The main…
Matched conditions: DLBCL
Phase: PHASE1 • Sponsor: Verismo Therapeutics • Aim: Disease control
Last updated May 26, 2026 08:14 UTC
-
Radioactive drug boosts CAR T-Cell therapy in Tough-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests a radioactive drug (131-I apamistamab) given before CAR T-cell therapy for people with relapsed or hard-to-treat B-cell acute lymphoblastic leukemia or diffuse large B-cell lymphoma. The goal is to find a safe dose and see if the combination is tolera…
Matched conditions: DLBCL
Phase: EARLY_PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 26, 2026 08:09 UTC
-
New hope for Tough-to-Treat lymphoma: targeted drug combo enters Late-Stage trial
Disease control Recruiting nowThis study tests whether adding the experimental drug zilovertamab vedotin to standard chemotherapy helps people with diffuse large B-cell lymphoma that has come back or not responded to prior treatment. About 290 adults will be randomly assigned to receive either the new combina…
Matched conditions: DLBCL
Phase: PHASE2, PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated May 11, 2026 20:38 UTC
-
New study aims to fill knowledge gaps for Hard-to-Treat lymphoma patients
Knowledge-focused Recruiting nowThis study gathers real-world data and samples from 800 people with large B-cell lymphoma who are either too frail for standard treatment or have not responded to initial therapy. The goal is to understand how these patients are managed and what their outcomes are, without testin…
Matched conditions: DLBCL
Sponsor: The Clatterbridge Cancer Centre NHS Foundation Trust • Aim: Knowledge-focused
Last updated May 26, 2026 08:18 UTC
-
DNA in blood may help tailor lymphoma therapy
Knowledge-focused Recruiting nowThis study looks at whether combining PET scans with a blood test that measures tumor DNA can better track how well treatment is working in people with early-stage diffuse large B-cell lymphoma (DLBCL). About 40 adults with untreated limited-stage DLBCL will receive standard chem…
Matched conditions: DLBCL
Phase: PHASE2 • Sponsor: University of Rochester • Aim: Knowledge-focused
Last updated May 19, 2026 11:48 UTC